HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Study on the reduction of chemotherapy induced neutropenia in mice using glucosaminylmuramyl dipeptide.

Abstract
Neutropenia is a common and often dose limiting side effect of some chemotherapy regimens. The aim of this study was to investigate the ability of an immunomodulator, glycosaminylmuramyl dipeptide (GMDP, CAS 78113-36-7, romurtide) to reduce chemotherapy induced neutropenia. BALB/c mice were treated with 200 mg kg-1 cyclophosphamide (CY) to induce a reversible neutropenia lasting approximately 6-7 days. There was no change in the duration or depth of neutropenia in mice treated with GMDP for 3 consecutive days (2.5 or 25 mg kg-1) starting the day after CY injection. In addition, at the doses used, the time of administration of GMDP relative to CY did not alter this response. However, a marked neutrophilia compared to controls was consistently observed in all cases. Neutrophil counts of up to 14 times the baseline value were measured 6-7 days after the induction of neutropenia. GMDP had no effect in the absence of CY. Less variation was seen in white cell counts of older non-SPF mice treated with CY. When the activity of GMDP (5 mg kg-1) was compared with G-CSF (granulocyte colony stimulating factor, 100 micrograms kg-1) in these animals, GMDP showed a consistent trend to reduce the length of neutropenia, however, under the conditions tested only G-CSF treatment resulted in a significant reduction in the duration of neutropenia. In the 12-week-old mice, the neutrophilia seen with both G-CSF and GMDP was much smaller than in the 8-week-old mice, and was not significantly different from that in control mice treated with CY alone.
AuthorsN A Armstrong, E J Bolton, D L Morris
JournalArzneimittel-Forschung (Arzneimittelforschung) Vol. 49 Issue 8 Pg. 716-20 (Aug 1999) ISSN: 0004-4172 [Print] Germany
PMID10483520 (Publication Type: Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • Antineoplastic Agents, Alkylating
  • Acetylmuramyl-Alanyl-Isoglutamine
  • glucosaminylmuramyl-2-alanine-D-isoglutamine
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Cyclophosphamide
Topics
  • Acetylmuramyl-Alanyl-Isoglutamine (analogs & derivatives, therapeutic use)
  • Adjuvants, Immunologic (therapeutic use)
  • Animals
  • Antineoplastic Agents, Alkylating
  • Behavior, Animal (drug effects)
  • Cyclophosphamide
  • Granulocyte-Macrophage Colony-Stimulating Factor (pharmacology)
  • Leukocyte Count (drug effects)
  • Mice
  • Mice, Inbred BALB C
  • Neutropenia (chemically induced, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: